
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT
- About


Armata Pharmaceuticals Inc (ARMP)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/02/2025: ARMP (1-star) has a low Upturn Star Rating. Not recommended to BUY.
1 Year Target Price $9
1 Year Target Price $9
0 | Strong Buy |
1 | Buy |
0 | Hold |
0 | Sell |
0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -72.96% | Avg. Invested days 24 | Today’s Advisory WEAK BUY |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 68.77M USD | Price to earnings Ratio - | 1Y Target Price 9 |
Price to earnings Ratio - | 1Y Target Price 9 | ||
Volume (30-day avg) 1 | Beta 0.97 | 52 Weeks Range 0.90 - 3.42 | Updated Date 07/2/2025 |
52 Weeks Range 0.90 - 3.42 | Updated Date 07/2/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.4 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -9.07% | Operating Margin (TTM) -1668.23% |
Management Effectiveness
Return on Assets (TTM) -24.32% | Return on Equity (TTM) -3439.35% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 191737610 | Price to Sales(TTM) 14.63 |
Enterprise Value 191737610 | Price to Sales(TTM) 14.63 | ||
Enterprise Value to Revenue 148.14 | Enterprise Value to EBITDA 14.22 | Shares Outstanding 36193500 | Shares Floating 11019467 |
Shares Outstanding 36193500 | Shares Floating 11019467 | ||
Percent Insiders 69.59 | Percent Institutions 2.05 |
Analyst Ratings
Rating 1 | Target Price 9 | Buy 1 | Strong Buy - |
Buy 1 | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Armata Pharmaceuticals Inc

Company Overview
History and Background
Armata Pharmaceuticals, Inc., (ticker ARMP) founded in 2003 (originally as AmpliPhi Biosciences), is a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant infections. They aim to combat the rise of antimicrobial resistance through phage-based therapies.
Core Business Areas
- Bacteriophage Therapeutics Development: Armata focuses on developing and commercializing bacteriophage-based therapies for antibiotic-resistant bacterial infections. This includes identifying, engineering, and manufacturing phages targeting specific pathogens.
- Phage Discovery and Screening: The company engages in the discovery and characterization of novel bacteriophages with therapeutic potential. They have a library of phages that are screened for activity against various bacterial strains.
Leadership and Structure
Sven H. Dreesbach is the CEO of Armata Pharmaceuticals, Inc. The company has a typical biotech organizational structure with departments dedicated to research and development, manufacturing, clinical trials, and regulatory affairs.
Top Products and Market Share
Key Offerings
- AP-PA02: A bacteriophage therapeutic targeting Pseudomonas aeruginosa infections, currently in Phase 1b/2a clinical trials. Competitors include traditional antibiotics and other companies developing novel antimicrobials.
- AP-SA02: A bacteriophage therapeutic targeting Staphylococcus aureus infections, including methicillin-resistant Staphylococcus aureus (MRSA). Competitors include traditional antibiotics and other companies developing novel antimicrobials.
Market Dynamics
Industry Overview
The pharmaceutical industry is facing a growing threat from antibiotic-resistant bacteria, creating a significant unmet medical need. This has led to increased investment and research in alternative therapies, including bacteriophage therapy.
Positioning
Armata is positioned as a leader in the development of bacteriophage-based therapies. Their focus on pathogen-specific phages gives them a potential advantage over broad-spectrum antibiotics.
Total Addressable Market (TAM)
The TAM for antimicrobial resistance is estimated to be in the tens of billions of dollars. Armata aims to capture a portion of this market by providing targeted phage therapies. The exact size depends on regulatory approvals and market penetration.
Upturn SWOT Analysis
Strengths
- Proprietary phage library
- Expertise in bacteriophage therapy
- Focus on specific pathogens
- Addressing unmet medical need
Weaknesses
- Limited financial resources
- Dependence on clinical trial success
- Relatively small size
- Novelty of phage therapy, regulatory hurdles
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
- Government funding for antimicrobial resistance research
- Increasing acceptance of phage therapy
Threats
- Failure in clinical trials
- Competition from other antimicrobial therapies
- Regulatory challenges
- Emergence of phage-resistant bacteria
Competitors and Market Share
Key Competitors
- CARS
- SNGX
- ADTX
Competitive Landscape
Armata competes with companies developing traditional antibiotics and other novel antimicrobial therapies. They have a competitive advantage in the phage therapy space.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been driven by research and development activities, clinical trial progress, and fundraising efforts.
Future Projections: Future growth depends on the successful completion of clinical trials, regulatory approvals, and commercialization of phage therapies. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include advancing clinical trials for AP-PA02 and AP-SA02, expanding the phage library, and seeking partnerships.
Summary
Armata Pharmaceuticals is a biotechnology company focusing on bacteriophage therapies for antibiotic-resistant infections and holds promise. Its success hinges on clinical trial results, regulatory approvals, and partnerships. Challenges remain in securing funding and navigating the regulatory landscape, but their focus on phage therapy positions them in a market with unmet medical needs. The success of clinical trials will have a great effect on the future of the company.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Armata Pharmaceuticals SEC Filings (10-K, 10-Q)
- Company Website
- Analyst Reports
- Industry News and Publications
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is estimated and may not be precise. Financial data should be verified with official SEC filings. The AI rating is based on available information and inherent uncertainties.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Armata Pharmaceuticals Inc
Exchange NYSE MKT | Headquaters Los Angeles, CA, United States | ||
IPO Launch date 2011-03-09 | CEO & Director Dr. Deborah L. Birx M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 60 | Website https://www.armatapharma.com |
Full time employees 60 | Website https://www.armatapharma.com |
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. operates as a subsidiary of Innoviva, Inc.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.